These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor. Yan GW; Chen Y; Li Y; Chen HF Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911 [TBL] [Abstract][Full Text] [Related]
24. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease. Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135 [TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands. Qiu X; Zhao GD; Tang LQ; Liu ZP Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846 [TBL] [Abstract][Full Text] [Related]
26. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations. Lee VS; Nimmanpipug P; Aruksakunwong O; Promsri S; Sompornpisut P; Hannongbua S J Mol Graph Model; 2007 Sep; 26(2):558-70. PubMed ID: 17468026 [TBL] [Abstract][Full Text] [Related]
27. Design, biologic evaluation, and SAR of novel pseudo-peptide incorporating benzheterocycles as HIV-1 protease inhibitors. He M; Zhang H; Yao X; Eckart M; Zuo E; Yang M Chem Biol Drug Des; 2010 Aug; 76(2):174-80. PubMed ID: 20572811 [TBL] [Abstract][Full Text] [Related]
37. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding. Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705 [TBL] [Abstract][Full Text] [Related]
38. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions. Seibold SA; Cukier RI Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840 [TBL] [Abstract][Full Text] [Related]
39. Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors. Andersson HO; Fridborg K; Löwgren S; Alterman M; Mühlman A; Björsne M; Garg N; Kvarnström I; Schaal W; Classon B; Karlén A; Danielsson UH; Ahlsén G; Nillroth U; Vrang L; Oberg B; Samuelsson B; Hallberg A; Unge T Eur J Biochem; 2003 Apr; 270(8):1746-58. PubMed ID: 12694187 [TBL] [Abstract][Full Text] [Related]
40. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem. Dunn BM; Pennington MW; Frase DC; Nash K Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]